WASHINGTON - At last, the FDA this week issued guidelines to the drug industry on pharmacogenomics, providing a framework for data submissions to supplement marketing applications and regulatory review, while also outlining a new mechanism for the voluntary submission of research data. (BioWorld Today) Read More
